## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in this application.

## LISTING OF CLAIMS

1. (Currently Amended) A composition comprising ~~at least one~~ a dsRNA oligonucleotide that targets a Bcl-2 A1 gene and a pharmaceutical carrier, wherein upon administration to a subject suffering from an ocular disease ~~associated with neovascularization or angiogenesis~~ said dsRNA inhibits expression of [[a]] the Bcl-2 A1 gene ~~associated with neovascularization or angiogenesis in an ocular disease~~.

2-22. (Canceled)

23. (Withdrawn - Currently Amended) A method for treating ocular disease in a subject, ~~wherein said disease is characterized at least in part by neovascularization,~~ comprising administering to said subject [[a]] the composition of claim 1 ~~comprising a dsRNA oligonucleotide and a pharmaceutically acceptable carrier, wherein said dsRNA oligonucleotide inhibits expression of a gene that promotes ocular neovascularization in said subject~~.

24-27. (Canceled)

28. (Withdrawn - Currently Amended) A method according to claim 23 where the ocular disease is selected from the group of stromal keratitis, uveitis, rubeosis, conjunctivitis, keratitis, blepharitis, sty, chalazion, iritis, macular degeneration, [[and]] retinopathy and eye cancer.

29-47. (Canceled)

48. (New) The composition of claim 1, wherein the dsRNA oligonucleotide targets AACCTGGATCAGGTCCAAGCA (SEQ ID NO: 291).

49. (New) The composition of claim 1, further comprising one or more additional dsRNA oligonucleotides that inhibit the expression of a gene of interest.

50. (New) The composition of claim 49, wherein the one or more additional double-stranded oligonucleotides inhibit the expression of a gene selected from the group consisting of: pro-angiogenesis genes, endothelial cell proliferation genes, herpes simplex virus genes and pro-inflammatory genes.

51. (New) The composition of claim 49, wherein the one or more additional double-stranded oligonucleotides inhibit the expression of a gene selected from the group consisting of: VEGF-A, VEGF-B, VEGF-C, VEGF-D, Placenta Growth Factor (PIGF), VEGF-R1, VEGF-R2, VEGF-R3, FGF-1, FGF-2, FGF-R1, FGF-R2, FGF-R3, FGF-R4, PDGF, PDGF-R, HER-2, HER-3, HER-4, HP BRCA2, NOXA-A, NOX, Novel ZF Protein, NFAT4, Co-factor of SP1, Ets2 Repressor, PKC related, PKC eta, Mitochondrial F0, Bcl-2 TF, Bcl-2 A1, RAP1, EGFR-RP, Endoplasmin 94, Folate BP, A-RAF, EGF Factor 8, APRIL, PGF Precursor, TNF, TNF-R1, TNF-R2 and IL-1.

52. (New) The composition of claim 1, further comprising a synthetic vector.

53. (New) The composition of claim 1, further comprising a cationic polymer.

54. (New) The composition of claim 53, wherein the cationic polymer is a histidine-lysine copolymer or polyethyleneimine (PEI).

55. (New) The composition of claim 1, further comprising a hydrophilic polymer.

56. (New) The composition of claim 55, wherein the hydrophilic polymer is PEG, polyoxazoline, polyacetal, HPMA or polyglycerol.

57. (New) The composition of claim 1, further comprising a targeting ligand.

58. (New) The composition of claim 57, wherein the targeting ligand is selected from the group consisting of: peptides, carbohydrates, vitamins, nutrients, antibodies and antibody fragments.

59. (New) A nucleic acid molecule that targets AACCTGGATCAGGTCCAAGCA (SEQ ID NO: 291) and inhibits expression of the Bcl-2 A1 gene.

60. (New) The nucleic acid molecule of claim 59 that is a double-stranded oligonucleotide.

61. (New) The nucleic acid molecule of claim 59 that is a small interfering RNA (siRNA).

62. (New) The siRNA of claim 61 that comprises a first strand that hybridizes to the mRNA portion encoded by AACCTGGATCAGGTCCAAGCA (SEQ ID NO: 291) and a second strand that hybridizes to the first strand.

63. (New) The siRNA of claim 61 that is 21 nucleotides long, optionally with a two nucleotide overhang at the 3' terminus of either strand or both strands.

64. (New) A composition comprising the oligonucleotide of claim 60 and a pharmaceutical carrier.

65. (New - Withdrawn) A method for decreasing the Bcl-2 A1 protein level in a cell comprising introducing into the cell the nucleic acid molecule of claim 59.

66. (New - Withdrawn) A method for treating an ocular disease in a subject comprising the step of administering to the subject the composition of claim 64.

67. (New - Withdrawn) The method of claim 66, wherein the disease is selected from the group consisting of: stromal keratitis, uveitis, rubeosis, conjunctivitis, keratitis, blepharitis, sty, chalazion, iritis, macular degeneration, retinopathy and eye cancer.